Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Nantahala Capital Management and its principals report a 4.50% beneficial stake in Aprea Therapeutics, Inc. common stock as of December 31, 2025. They collectively report beneficial ownership of 411,520 shares, including 205,760 shares that can be acquired within sixty days through exercise of warrants.
Nantahala, Wilmot B. Harkey, and Daniel Mack report zero sole voting or dispositive power and shared voting and dispositive power over all 411,520 shares. They state the holdings are owned in the ordinary course of business and are not intended to change or influence control of Aprea Therapeutics.
Aprea Therapeutics’ President and CEO Gilad Oren, who is also a director, reported buying 28,100 shares of common stock in a private placement that closed on January 30, 2026 at $0.89 per share. After this purchase, he directly holds 373,720 common shares, with additional indirect holdings of 1,200 shares by his daughter and 600 shares by his son.
Oren also received 28,100 common warrants with an exercise price of $0.765 per share, immediately exercisable but subject to limits so his ownership generally cannot exceed 4.99% of outstanding common stock or 9.99% of combined voting power. These warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144 on a cashless basis.
Aprea Therapeutics’ Senior Vice President and CFO John P. Hamill bought 5,700 shares of common stock in a private placement on January 30, 2026 at $0.89 per share, bringing his direct holdings to 33,433 shares.
He also received common warrants to purchase up to 5,700 additional shares at an exercise price of $0.765 per share. The warrants are immediately exercisable but include caps so his and his affiliates’ beneficial ownership cannot exceed 4.99% of common stock or 9.99% of total voting power after exercise. The warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 6,288,857 shares of common stock or pre-funded warrants, together with common stock warrants to purchase up to 6,288,857 shares. The combined effective offering price per share or pre-funded warrant plus accompanying warrant is $0.89, for expected aggregate gross proceeds of approximately $5.6 million.
The common warrants have a $0.765 exercise price, a two-year term starting after resale registration effectiveness or Rule 144 eligibility, and 4.99% or 9.99% ownership caps, with cashless exercise allowed in certain cases. Aprea agreed to file and maintain a resale registration statement and accepted issuance and variable-rate financing restrictions for defined periods. Maxim Group LLC will receive a 7% cash fee on gross proceeds and reimbursement of up to $35,000 in expenses. The company also reported a first unconfirmed partial response in its ongoing Phase 1 ACESOT-1051 study and updated its corporate presentation.
AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman report their ownership of Aprea Therapeutics, Inc. common stock in an amended Schedule 13G (Amendment No. 3) as of December 31, 2025. The reporting group states beneficial ownership of 651,747 shares of common stock, including 281,206 shares issuable upon exercise of warrants, representing 9.9% of Aprea’s outstanding common stock. They report sole voting power over 370,541 shares and sole dispositive power over the full 651,747 shares. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Aprea Therapeutics.
Aprea Therapeutics, Inc. reported that it received a deficiency letter from Nasdaq because its common stock has closed below the required $1.00 minimum bid price for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading, and the stock will continue to trade on The Nasdaq Capital Market under the symbol APRE.
The company has 180 calendar days, until July 22, 2026, to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If it still meets other listing standards, it may qualify for a second 180-day period. If compliance is not regained, the stock could be delisted, although the company would have the right to appeal. Aprea is monitoring its share price and may consider actions such as a reverse stock split, but there is no assurance it will meet the minimum bid price or other Nasdaq rules.
Aprea Therapeutics, Inc. filed a current report to note that it has updated its corporate presentation slide deck as of January 9, 2026. The refreshed investor presentation is included as Exhibit 99.1 and is incorporated by reference, meaning it is treated as part of the official disclosure record. The filing does not describe the specific changes to the presentation, only that a new January 2026 version is now available.
Aprea Therapeutics, Inc. is registering 5,503,556 shares of common stock for potential resale by investors from a December 2025 private placement and related warrants. The shares consist of 26,459 already issued shares, 2,596,564 shares underlying pre-funded warrants, 2,623,023 shares underlying common warrants, and 257,510 warrant shares issued to Maxim Group LLC as compensation. Aprea will not receive proceeds from any resale, but may receive cash if warrants are exercised at $1.04 or $0.001 per share, which it plans to use for clinical trials, working capital and general corporate purposes. The registered securities represent about 79% of the 6,993,838 shares outstanding as of December 10, 2025, creating potential selling pressure on the stock. Aprea is a clinical-stage oncology company developing synthetic lethality therapies, including WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119, both in early-stage clinical development.
Aprea Therapeutics, Inc. reported that a director purchased 21,459 shares of common stock in a private placement on December 10, 2025 at a price of $1.165 per share and received accompanying common warrants to purchase up to 21,459 additional shares at an exercise price of $1.04.
After the transaction, the report shows 256,155 shares held directly, 602 shares held by a spouse and 21,459 common warrants. The warrants are immediately exercisable but cannot be used if exercise would push the holder above 4.99% beneficial ownership of common stock or 9.99% of the issuer’s total voting power, and they expire five years after the earlier of a registration of the underlying shares or the date those shares become eligible for resale under Rule 144 on a cashless basis.
Aprea Therapeutics, Inc. reported an insider purchase by its Senior Vice President, Chief Financial Officer and Principal Financial & Accounting Officer, John Hamill. On December 10, 2025, he acquired 5,000 shares of common stock in a private placement at a purchase price of $1.165 per share, bringing his directly held common stock to 27,733 shares.
As part of the same private placement, he also received common warrants to purchase up to 5,000 additional shares of common stock at an exercise price of $1.04 per share. The warrants are immediately exercisable but contain beneficial ownership limits that generally cap holdings at 4.99% of outstanding common stock or 9.99% of combined voting power. The warrants expire on the fifth anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.